A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults

Trial Profile

A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Emtricitabine/tenofovir; Lamivudine
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms Gemini 1
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top